{
    "nct_id": "NCT04904120",
    "official_title": "A Phase 1 Cross-over Biodistribution Study of [203Pb]VMT01 for Single Photon Emission Computed Tomography (SPECT) Imaging and [68Ga]VMT02 for Positron Emission Tomography (PET) Imaging of Stage IV Metastatic Melanoma",
    "inclusion_criteria": "1. Diagnosed with Stage IV metastatic melanoma, or inoperable Stage III equivalent\n2. Baseline fluorodeoxyglucose (FDG)-PET scan available from within 30 days prior to date of enrollment\n3. Blood counts and metabolic results within protocol limits within 14 days prior to enrollment\n4. Ability to lie flat and still for a minimum of two hours for imaging\n5. Male and female participants with reproductive potential must agree to use highly effective contraception in preparation of the study, during the study, and for 4 weeks following the last dose of an investigative imaging agent\n6. Documented life expectancy of at least 3 months\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 89 Years",
    "exclusion_criteria": "1. Active secondary malignancy\n2. Prior treatment (for any reason) with radioactive nuclides; imaging tracers are acceptable\n3. Pregnancy or breast feeding a child\n4. Uncontrolled infection\n5. Treatment with another investigational drug within 30 days prior to enrollment date\n6. Any treatment with BRAF inhibitors since the baseline FDG-PET scan or plans for such treatment during the study\n7. Kidney function not within protocol limits\n8. BMI>40 kg/m2\n9. History of a condition resulting in anaphylaxis or angioedema",
    "miscellaneous_criteria": ""
}